Market Sniffer
Events, Trading Views and Industry Insights
Tuesday, January 10, 2023
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
via Kuala Lumpur Week https://ift.tt/PaHOgft
Newer Post
Older Post
Home